Biocon Secures Licensed Launch Dates for Pebrilzo After Genentech Settlement

Biocon and Genentech reached a global patent settlement and licence agreement, allowing Biocon to launch its pertuzumab biosimilar Pebrilzo across key markets from 2026 onward.